MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00432-022-04215-7

Медицинская библиотека · Journal of cancer research and clinical oncology · 2022

Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer.

Takeuchi Eiji, Kondo Kensuke, Okano Yoshio, Kunishige Michihiro, Kondo Yoshihiro, Kadota Naoki, Machida Hisanori, Hatakeyama Nobuo, Naruse Keishi, Ogino Hirokazu, Nokihara Hiroshi, Shinohara Tsutomu, Nishioka Yasuhiko

СтатьяПеревод пока не подготовлен

Аннотация

PURPOSE: Immune checkpoint inhibitors (ICI) are a promising treatment, but may cause hyperprogressive disease and early death. The present study investigated early mortality factors in ICI monotherapy for lung cancer.

PATIENTS AND

METHODS

We retrospectively reviewed all patients diagnosed with advanced or metastatic non-small cell lung cancer (NSCLC) and treated with ICI monotherapy (nivolumab, pembrolizumab, and atezolizumab) between March 2016 and August 2021 at National Hospital Organization Kochi Hospital and Tokushima University. Early death was defined as patients who died within 60 days of ICI treatment.

RESULTS

A total of 166 patients were included. The majority of patients (87%) had an Eastern cooperative oncology group (ECOG) Performance status (PS) of 0/1. There were 21 early deaths. Significant differences were observed in ECOG PS, the histological type, liver metastasis, tumor size, the white blood cell count, neutrophils (%), lymphocytes (%), the neutrophil-to-lymphocyte ratio in serum (sNLR), C-reactive protein (CRP), and albumin between the groups with or without early death. Univariate logistic regression analyses identified ECOG PS score ≥ 2, liver metastasis, tumor size ≥ 5 cm, neutrophils ≥ 69%, lymphocytes < 22%, sNLR ≥ 4, CRP ≥ 1 mg/dl, and albumin < 3.58 g/dl as significant risk factors for early death. A multivariate logistic regression analysis revealed that liver metastasis (Odds ratio [OR], 10.3; p = 0.008), ECOG PS score ≥ 2 (OR, 8.0; p = 0.007), and a smoking history (OR, 0.1; p = 0.03) were significant risk factors for early death.

CONCLUSION

Liver metastases, ECOG PS score ≥ 2, and a non-smoking history are early mortality factors in ICI monotherapy for advanced or metastatic NSCLC.

Для цитирования: Takeuchi Eiji, Kondo Kensuke, Okano Yoshio, Kunishige Michihiro, Kondo Yoshihiro, Kadota Naoki, Machida Hisanori, Hatakeyama Nobuo, Naruse Keishi, Ogino Hirokazu, Nokihara Hiroshi, Shinohara Tsutomu, Nishioka Yasuhiko. Early mortality factors in immune checkpoint inhibitor monotherapy for advanced or metastatic non-small cell lung cancer.. Journal of cancer research and clinical oncology. 2022. DOI: 10.1007/s00432-022-04215-7.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.